Transform Wealth LLC Sells 105 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Transform Wealth LLC decreased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,006 shares of the medical equipment provider’s stock after selling 105 shares during the period. Transform Wealth LLC’s holdings in Intuitive Surgical were worth $2,459,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Creekmur Asset Management LLC lifted its position in shares of Intuitive Surgical by 200.0% during the 1st quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 42 shares during the period. Ridgewood Investments LLC bought a new position in shares of Intuitive Surgical during the second quarter valued at $26,000. Delos Wealth Advisors LLC boosted its stake in shares of Intuitive Surgical by 380.0% in the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 57 shares in the last quarter. LRI Investments LLC bought a new stake in shares of Intuitive Surgical in the 1st quarter worth about $30,000. Finally, LGT Financial Advisors LLC increased its position in shares of Intuitive Surgical by 415.4% during the 2nd quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 54 shares in the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Intuitive Surgical

In related news, EVP Myriam Curet sold 2,818 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the sale, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $136,522.74. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the completion of the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at $1,461,006.84. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Myriam Curet sold 2,818 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total transaction of $1,291,010.34. Following the completion of the sale, the executive vice president now directly owns 298 shares in the company, valued at $136,522.74. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 53,120 shares of company stock valued at $25,528,753 over the last three months. 0.90% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Evercore ISI upped their price objective on shares of Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. BTIG Research increased their price target on Intuitive Surgical from $494.00 to $518.00 and gave the stock a “buy” rating in a research report on Monday. Piper Sandler raised their price target on Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Stifel Nicolaus boosted their price objective on Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research note on Friday, July 19th. Finally, Barclays raised their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $467.55.

Intuitive Surgical Stock Down 0.3 %

Shares of Intuitive Surgical stock traded down $1.46 during trading on Wednesday, reaching $477.01. 266,117 shares of the company were exchanged, compared to its average volume of 1,459,418. The business has a 50-day moving average price of $481.94 and a 200-day moving average price of $436.37. The firm has a market capitalization of $169.20 billion, a price-to-earnings ratio of 86.37, a P/E/G ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $496.48.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the prior year, the business posted $1.18 EPS. Intuitive Surgical’s revenue was up 14.5% on a year-over-year basis. On average, equities research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.